DYNLT1 Antibody

What are the recommended applications for DYNLT1 antibodies?

DYNLT1 antibodies have been validated for multiple research applications including:

It is crucial to perform optimization for each specific experimental system as detection sensitivity may vary depending on tissue type and target expression levels .

How should DYNLT1 antibodies be stored for optimal performance?

For most DYNLT1 antibodies, the following storage conditions are recommended:

• Store at -20°C for polyclonal antibodies in glycerol-based buffers

• Store at -80°C for monoclonal antibodies in PBS-only formulations

• Maintain aliquots to avoid repeated freeze-thaw cycles, which can degrade antibody performance

• Typical shelf life is approximately one year when stored properly

• For antibodies in 0.02% sodium azide and 50% glycerol (pH 7.3), aliquoting is not necessary for -20°C storage

Some formulations (particularly PBS-only) are more sensitive to storage conditions, so always verify manufacturer-specific recommendations .

What is the molecular weight of DYNLT1 protein that should be detected?

DYNLT1 has the following molecular characteristics:

• Calculated molecular weight: 12 kDa (113 amino acids)

• Observed molecular weight: 12 kDa in SDS-PAGE

• Gene ID (NCBI): 6993

• UniProt accession: P63172

Researchers should expect to detect a single band at approximately 12 kDa in Western blot applications. Any additional bands may indicate non-specific binding or post-translational modifications .

How is DYNLT1 implicated in cancer research, particularly breast cancer?

Recent research has demonstrated significant associations between DYNLT1 and breast carcinoma (BC):

• DYNLT1 is overexpressed in breast cancer tissues compared to normal breast tissues

• High DYNLT1 expression correlates with poor relapse-free survival in breast cancer patients

• Functional studies show DYNLT1 promotes breast cancer development through:

  • Enhanced proliferation of MDA-MB-231 cells

  • Increased cell migration capacity

  • Promotion of metastatic potential

Knockdown experiments demonstrate that reduced DYNLT1 expression inhibits colony formation, cell proliferation, migration, and invasion in breast cancer cell lines. These findings suggest DYNLT1 may serve as both a diagnostic and prognostic indicator in breast cancer .

Mechanistically, DYNLT1 appears to influence:

• DNA damage repair pathways

• Cell cycle regulation

• Tumor-infiltrating lymphocyte profiles

• TGF-beta response patterns

These roles collectively contribute to DYNLT1's potential significance in predicting immunotherapy response in breast cancer patients .

What is known about DYNLT1's interactions with viral proteins, particularly HIV-1?

DYNLT1 has been implicated in virus-host interactions, with particular relevance to HIV-1 infection:

• DYNLT1 directly interacts with HIV-1 integrase (IN) but not with capsid (CA), matrix (MA), or reverse transcriptase (RT) proteins

• This interaction occurs through specific motifs (52GQVD and 250VIQD) in HIV-1 integrase

• Unlike DYNLT1, related dynein adapter proteins DYNLL1 and p150Glued show different patterns in viral interactions

Functional significance:

• DYNLT1 knockdown does not significantly affect HIV-1 reverse transcription

• This contrasts with DYNLL1, which is required for efficient HIV-1 reverse transcription

• The differential roles of dynein adapter proteins suggest specific and non-redundant functions in viral replication

Interestingly, DYNLT1 also interacts with murine leukemia virus (MMLV) integrase, suggesting a potentially conserved role in retroviral biology .

What protein-protein interactions involving DYNLT1 are relevant for nuclear transport research?

DYNLT1 exhibits important interactions with nucleoporins and other nuclear transport factors:

• DYNLT1 interacts with FG repeat nucleoporins, including:

  • NUP98 (binds to the FG repeat region)

  • NUP153 (interaction slightly reduced by deletion of N- or C-terminus)

  • NUP62 (binding almost completely abolished by removal of FG-repeat containing N-terminus)

These interactions have been validated through:

• GST pulldown assays with in vitro translated nucleoporins

• Co-immunoprecipitation of endogenous proteins from K562 cells

• Immunolocalization showing DYNLT1 enrichment at the nuclear rim

Functionally, DYNLT1 appears to play a role in:

• The oncogenic potential of NUP98-HOXA9 fusion proteins in acute myeloid leukemia

• Regulation of transcriptional activity by modulating promoter interactions

• Cell proliferation, as demonstrated by inhibition of cell proliferation upon DYNLT1 knockdown in human CD34+ primary cells expressing NUP98-HOXA9

How can researchers develop and validate DYNLT1 antibodies for specific applications?

Based on published methodologies, researchers can consider the following approach for antibody development:

• Antigen Selection and Production:

  • Express recombinant DYNLT1 protein (full-length is preferable)

  • Common expression systems include E. coli with pGEX vectors for GST-fusion proteins

  • Purify using affinity chromatography (GST or His-tag based methods)

• Immunization and Serum Collection:

  • Immunize rabbits for polyclonal or mice for monoclonal antibodies

  • Collect test bleeds to evaluate antibody titer

  • Select production bleeds with highest reactivity against target protein

• Purification Strategy:

  • Pre-clear serum using bacterial lysate expressing empty vector

  • Use affinity chromatography with immobilized DYNLT1 protein

  • Elution options include 1M NaCl, 0.1M Glycine pH 2.5, or combinations with CHAPS

  • Neutralize acidic fractions immediately with Tris-base buffer

• Validation Testing:

  • Western blot against both recombinant protein and endogenous DYNLT1

  • Knockdown validation using shRNA/siRNA against DYNLT1

  • Immunofluorescence with appropriate controls

  • Cross-reactivity testing against related proteins

For monoclonal antibody development, additional hybridoma selection and cloning steps are required following immunization .

What controls should be included when using DYNLT1 antibodies in experimental workflows?

Robust experimental design should include the following controls when working with DYNLT1 antibodies:

Positive Controls:

• Human brain and heart tissues (validated for WB)

• Mouse skeletal muscle tissue (validated for IP)

• Human pancreas tissue (validated for IHC)

• Mouse testis tissue (validated for IF-P)

• SH-SY5Y cells (validated for IF/ICC)

Negative Controls:

• Secondary antibody only (no primary antibody)

• Isotype control (unrelated antibody of same isotype)

• DYNLT1 knockdown samples:

  • shRNA validation has been performed using pRFP-C-RS vector systems

  • siRNA approaches have been successful in primary human CD34+ cells

Validation Approaches:

• Peptide competition assays to confirm specificity

• Multiple antibodies targeting different epitopes

• Recombinant expression of tagged DYNLT1 as size reference

• Cross-species validation (human, mouse, and rat show high conservation)

How can researchers optimize DYNLT1 detection in challenging tissue samples?

For optimizing DYNLT1 detection in difficult samples, consider the following methodological adjustments:

For Immunohistochemistry:

• Antigen retrieval optimization is critical:

  • Primary recommendation: TE buffer pH 9.0

  • Alternative method: Citrate buffer pH 6.0

• Extended incubation times (overnight at 4°C) may improve sensitivity

• Signal amplification systems can enhance detection in low-expression samples

• Fresh frozen samples may provide better results than FFPE in some cases

For Western Blot:

• Extraction buffer optimization:

  • Include phosphatase inhibitors

  • Use 0.12% NP-40 lysis buffer with protease inhibitor cocktail for co-IP applications

• Sample preparation:

  • Heat samples at 95°C for 5 minutes in reducing conditions

  • Avoid excessive heating which may cause protein aggregation

• Transfer optimization:

  • Use PVDF membranes for better protein retention

  • Consider semi-dry transfer systems for small proteins like DYNLT1

For Immunofluorescence:

• Fixation method comparison (4% paraformaldehyde vs. methanol)

• Permeabilization optimization (0.1-0.5% Triton X-100)

• Signal amplification using tyramide signal amplification

• Confocal microscopy with optimal pinhole settings for capturing subcellular distribution

How can DYNLT1 antibodies be utilized in cancer research beyond breast cancer?

DYNLT1 antibodies have applications in multiple cancer types beyond breast cancer:

Glioblastoma Research:

• DYNLT1 promotes glioblastoma progression

• Expression correlates with tumor-node-metastasis (TNM) grade

• Antibodies can be used to assess expression levels in patient samples and cell lines

Gastric Cancer Studies:

• DYNLT1 participates in the miR-15b-3p/Caspase-3/Caspase-9 signaling pathway

• Contributes to malignant transformation

• Antibodies enable evaluation of expression correlation with clinical parameters

Leukemia Research:

• DYNLT1 interacts with the NUP98-HOXA9 fusion protein in acute myeloid leukemia

• Knockdown inhibits cell proliferation in human CD34+ cells expressing this fusion

• Antibodies facilitate mechanistic studies of leukemogenic processes

Methodological applications include:

• Tissue microarray analysis for expression profiling across tumor types

• Co-immunoprecipitation to identify cancer-specific interaction partners

• Chromatin immunoprecipitation to assess potential transcriptional roles

• Proximity ligation assays to validate protein-protein interactions in situ

What is the significance of DYNLT1 in neurological research?

DYNLT1 has several neurological functions that make it relevant for neuroscience research:

Developmental Neurobiology:

• DYNLT1 (Tctex-1) is selectively enriched in proliferating neural progenitors in both embryonic and adult brains

• Genetic knockdown promotes neurogenesis, suggesting a regulatory role in cortical neurogenesis

• Antibodies enable tracking of expression patterns during neural development

Neurodegenerative Disease Research:

• DYNLT1 has been linked to Huntington's disease pathology

• Involved in intracellular transport mechanisms crucial for neuronal function

• May participate in protein aggregation or clearance processes

Neuronal Morphogenesis:

• Functions in neuronal morphogenesis independent of cytoplasmic dynein

• Role appears coupled to actin cytoskeleton regulation by enhancing Rac1 activity

• May be regulated through association with G-protein beta-gamma dimers

Research applications include:

• Immunohistochemical analysis of brain tissue during development and in disease states

• Live cell imaging using antibodies to track DYNLT1 dynamics

• Correlation of expression patterns with neurogenesis markers

• Investigation of DYNLT1's role in axonal transport and neuronal maintenance

How can DYNLT1 antibodies contribute to the study of viral pathogenesis?

DYNLT1 antibodies provide valuable tools for investigating host-virus interactions:

HIV-1 Research:

• Enables detection of DYNLT1-HIV integrase interactions

• Allows assessment of cellular factors in viral replication cycles

• Facilitates understanding of dynein-mediated transport in viral infection

Retroviral Studies:

• DYNLT1 is involved in intracellular targeting of D-type retrovirus gag polyproteins

• Contributes to cytoplasmic assembly site localization

• Antibodies help elucidate trafficking mechanisms

Methodological Approaches:

• Co-immunoprecipitation to capture virus-host protein complexes

• Immunofluorescence to track viral component localization

• Proximity ligation assays to visualize protein interactions in situ

• DYNLT1 knockdown/knockout systems to assess functional impact on viral replication

Research implications:

• Potential for identifying novel antiviral targets

• Understanding cellular machinery hijacked during infection

• Elucidating mechanisms of viral nuclear import and assembly

• Development of host-directed therapeutic strategies

What criteria should researchers use to select between monoclonal and polyclonal DYNLT1 antibodies?

Selection between monoclonal and polyclonal DYNLT1 antibodies should be based on specific research needs:

Polyclonal Antibodies (e.g., 11954-1-AP):

• Advantages:

  • Higher sensitivity due to recognition of multiple epitopes

  • Better for detecting denatured proteins in Western blot

  • More robust against minor antigen changes or modifications

• Applications:

  • Broad detection across species (human, mouse, rat)

  • Initial screening of DYNLT1 expression

  • Applications requiring high sensitivity

• Storage: -20°C in glycerol-based buffers

Monoclonal Antibodies (e.g., 68312-1-PBS, 7A9):

• Advantages:

  • Consistent lot-to-lot reproducibility

  • Higher specificity for particular epitopes

  • Lower background in certain applications

• Applications:

  • Specific detection of defined epitopes

  • Flow cytometry and immunoprecipitation

  • Experiments requiring absolute consistency

• Storage: -80°C for PBS formulations

Selection Criteria Matrix:

Consider validation status for your specific application and species when making selection .

How should researchers interpret DYNLT1 antibody validation data?

Proper interpretation of validation data is essential for experimental success:

Western Blot Validation:

• Verify detection of single band at ~12 kDa in positive control samples

• Check for validated tissues/cells (human brain/heart, Sp2/0 cells)

• Evaluate knockdown/knockout validation showing band reduction

• Assess lot-specific validation if available

Immunohistochemistry/Immunofluorescence Validation:

• Review tissue-specific staining patterns (pancreas, testis)

• Compare subcellular localization with established patterns:

  • Cytoplasmic distribution with enrichment at nuclear rim

  • Association with microtubule structures

• Evaluate specificity through peptide blocking or KO controls

Cross-Reactivity Assessment:

• Review testing against protein arrays when available

• Check cross-species reactivity (human, mouse, rat)

• Note any potential cross-reactivity with related proteins

• Consider epitope sequence conservation across species

When interpreting publications using DYNLT1 antibodies, always verify:

• The specific clone/catalog number used

• Validation performed specifically for the application

• Controls included in the study

• Dilution and protocol optimizations performed

What quality control measures ensure reliable results with DYNLT1 antibodies?

Implementing stringent quality control measures helps ensure experimental reliability:

Pre-Experiment Validation:

• Perform titration experiments to determine optimal concentration

  • WB: Test dilutions from 1:300-1:600

  • IHC: Test range from 1:20-1:200

  • IF: Test range from 1:50-1:500

• Include positive control samples (tissue/cell types with confirmed expression)

• Incorporate negative controls (secondary-only, isotype controls)

• Consider pre-adsorption with immunizing peptide to confirm specificity

Batch Testing:

• When receiving new antibody lots, compare with previous lots using:

  • Side-by-side Western blot

  • Standardized positive controls

  • Consistent imaging parameters

• Document lot-specific optimal concentrations

Long-Term Monitoring:

• Maintain positive control lysates/tissues as reference standards

• Track antibody performance over time (signal:noise ratio)

• Monitor for changes in background or specificity

• Document freeze-thaw cycles and storage conditions

Experimental Controls:

• Include DYNLT1 knockdown/overexpression controls

• Use multiple antibodies targeting different epitopes when possible

• Employ orthogonal detection methods to confirm findings

• Consider tagged DYNLT1 constructs as additional controls

Following these quality control measures will maximize reproducibility and reliability of DYNLT1 antibody-based experiments .